July 8, 2024
Finally! FDA Issues Updated Draft Guidance on Diversity Action Plans Mandated by FDORA
February 20, 2024
FDA Issues Draft Guidance on Use of Data Monitoring Committees in Clinical Trials
January 10, 2024
FDA Issues Proposed Rule Classifying Certain Wound Dressings and Liquid Wound Washes For the First Time
January 3, 2024
FDA Issues Final Rule Permitting IRB Waiver or Alteration of Informed Consent for Certain Minimal Risk Clinical Investigations
August 24, 2023
FDA Issues Draft Guidance for Obtaining Postmarket Data on Underrepresented Populations in Drug Clinical Trials
June 30, 2023
FDA Finalizes Guidance on Presenting Quantitative Efficacy and Risk Information in DTC Promotion
March 7, 2023
FDA Issues Draft Guidance on “External Controls” in Clinical Trials to Support Safety and Efficacy of a Drug
November 14, 2022
FDA (Finally!) Issues Proposed Rule to Amend FDA Regulations on the Protection of Human Subjects and Institutional Review Boards
November 1, 2022
Clinical Data Integrity: FDA and DOJ Enforcement Priorities
March 23, 2020
U.S. and EU Regulators and Institutions Issue Guidance on Clinical Trial Conduct during COVID-19 Pandemic
February 1, 2017
HHS Issues Final Rule that Substantially Revises the Federal Policy for the Protection of Human Subjects
December 12, 2016
FDA Identifies Fifteen Hospitals with Failures to Comply with User Facility Requirements for Medical Device Reporting